Brand name versus generic warfarin: A systematic review of the literature

Pharmacotherapy

Volumn 31, Issue 4, 2011, Pages 386-393

  Dentali, Francesco ^a   Donadini, Marco P ^a,b   Clark, Nathan ^c   Crowther, Mark A ^b   Garcia, David ^d   Hylek, Elaine ^e   Witt, Dan M ^c   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c Clinical Pharmacy Anticoagulation Service   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Generics; Systematic review; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; GENERIC DRUG; WARFARIN;

ADULT; AGED; BLEEDING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; NOMENCLATURE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANTICOAGULANTS; COHORT STUDIES; DRUGS, GENERIC; HUMANS; INTERNATIONAL NORMALIZED RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; WARFARIN;

EID: 79953715346     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.4.386     Document Type: Review

References (16)

1. U.S. Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf. Accessed December 13, 2009.
2. U.S. Food and Drug Administration. Criteria and evidence to assess actual or potential bioequivalence problems. 21CFR320.33. Available from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=320.33. Accessed December 13, 2009.
3. Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-8.
4. Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther 2003;74:215-21. (Pubitemid 37083097)
5. Witt DM, Tillman DJ, Evans CM, Plotkin TV, Sadler MA. Evaluation of the clinical and economic impact of brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003;23:360-8. (Pubitemid 36259340)
6. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep 1998;19:49-59. (Pubitemid 28090870)
7. Handler J, Nguyen TT, Rush S, Pham NT. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prev Cardiol 1998;4;13-20.
8. Swenson CN, Fundak G. Observational study of switching warfarin sodium products in a managed care organization. Am J Health Syst Pharm 2000;57:452-5. (Pubitemid 30127279)
9. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
10. Jadad AR, Moor RA, Carroll D, et al. Assessing the quality of reports of randomized controlled trials. Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
11. Stroup DF, Berlin JA, Morton SC, et al, for the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283:2008-12. (Pubitemid 30214957)
12. Weibert RT, Yeager BF, Wittkowsky AK, et al. A randomized, crossover comparison of warfarin products in the treatment of atrial fibrillation. Ann Pharmacother 2000;34:981-8. (Pubitemid 30660773)
13. Lee HL, Kan CD, Yang YJ. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. Clin Ther 2005;27:309-19.
14. Pereira JA, Holbrook AM, Goldsmith C, et al. Are brand name and genric warfarin interchangeable? Multiple N-of-1 randomized, cross-over trials. Ann Pharmacother 2005;39:1188-93. (Pubitemid 40943167)
15. Milligan PE, Banet GA, Waterman AD, Gatchel SK, Gage BF. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002;36:764-8. (Pubitemid 34517402)
16. Paterson JM, Mamdani M, Juurlink DN, Naglie G, Laupacis A, Stukel TA. Clinical consequences of generic warfarin substitution: an ecological study. JAMA 2006;296:1969-72. (Pubitemid 44631442)